ARCHIVES

FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 13 | March 30, 2001

Download PDF Visit The Full Archive

Related Articles

National Action Plan: Return $14 Million To NCI, Committee Tells Shalala

February 14, 1997

John Ultmann, Chicago’s Outspoken Director, Heads In Retirement

August 30, 1991

Conference On Delayed Consequences Of Cancer Therapy Scheduled Jan. 9-11

January 3, 1975

Unwanted Distinction: MSKCC Bars Zaltrap From Formulary, Triggering Debate Over Drug Pricing

November 1, 2012

RFA/PA/Drug Group Announcement Limited

May 6, 1988

In Brief: NCAB Meeting Set For Oct. 3-5; Second Workshop On Tumor Cell Cloning Jan. 3-5

August 24, 1979